Melanoma trial: NCT01400451
| NCT01400451 [view on www.clinicaltrials.gov] | |
| Phase I/II Ipilimumab Vemurafenib Combo | |
| Recruiting | |
| Phase 1, Phase 2 | |
| name: For participation information at a USA site use a phone number below. For site information outside the USA please email:; ; email: Clinical.Trials@bms.com | |
| Zelboraf Yervoy | |
| Immunotherapies CTLA4 Inhibitors BRAF inhibitors | |
| Bristol-Myers Squibb, Roche-Genentech |